DGAP-News: Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN(R) for the Treatment of Chronic Diabetic Macular Edema
Alimera Sciences, Inc.
28.02.2012 12:30
—————————————————————————
— ILUVIEN(r) expected to be the first sustained release pharmaceutical in the
European Union to treat diabetic macular edema (DME)
— ILUVIEN expected to be indicated for chronic DME considered insufficiently
responsive to available therapies
ATLANTA, Feb. 28, 2012 (GLOBE NEWSWIRE) — Alimera Sciences, Inc.,
(Nasdaq:ALIM) (Alimera), a biopharmaceutical company th
